AGC Biologics is a global CDMO providing pharmaceutical development and manufacturing services for protein-based biologics and cell and gene therapies. With seven facilities and teams of scientists across three continents, we have the resources and the available capacity you need to accelerate your race to GMP. From development, to clinical trials, to full-scale commercialization, we can help you reach your goals at any stage in the drug development and manufacturing process. We specialize in the following modalities and substances, mammalian and microbial-based therapeutic proteins, recombinant DNA, plasmid DNA (pDNA), viral vectors, Messenger RNA (mRNA) and genetically engineered cells. Our services range from Process Development, Analytical Development, cGMP Manufacturing, Quality Control and Quality Assurance and Process Validation. We forge exceptionally strong partnerships with our clients and we never lose sight of our commitment to deliver reliable and compliant drug substance. | AGC Biologics is a global CDMO providing pharmaceutical development and manufacturing services for protein-based biologics and cell and gene therapies. With eight facilities and teams of scientists across three continents, we have the resources and the available capacity you need to accelerate your race to GMP. From development, to clinical trials, to full-scale commercialization, we can help you reach your goals at any stage in the drug development and manufacturing process. We specialize in the following modalities and substances, mammalian and microbial-based therapeutic proteins, recombinant DNA, plasmid DNA (pDNA), viral vectors, Messenger RNA (mRNA) and genetically engineered cells. Our services range from Process Development, Analytical Development, cGMP Manufacturing, Quality Control and Quality Assurance and Process Validation. We forge exceptionally strong partnerships with our clients and we never lose sight of our commitment to deliver reliable and compliant drug substance. | AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, to provide friendly and expert services. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. We currently employ more than 2,800 Team Members worldwide. AGC Biologics is a part of AGC Inc.’s Life Science Business. The Life Science Business runs 10+ facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit www.agcbio.com. | x
adMare BioInnovations
With a strong track record of globally-competitive scientific discovery, Canadian life sciences are primed to lead the world. To make this a reality, adMare BioInnovations uses its scientific and commercial expertise, specialized R&D infrastructure, and seed capital to build strong life sciences companies, develop robust ecosystems, and foster industry-ready talent. It re-invests its returns into the Canadian industry to ensure its long-term sustainability. adMare currently has 28 portfolio companies that have attracted $1.4 billion of risk capital, have a combined value of $3 billion, and have created over 1,000 jobs in Canada. For more information, please go to www.admarebio.com. | With a strong track record of globally-competitive scientific discovery, Canadian life sciences are primed to lead the world. To make this a reality, adMare BioInnovations uses its scientific and commercial expertise, specialized R&D infrastructure, and seed capital to build strong life sciences companies, develop robust ecosystems, and foster industry-ready talent. It re-invests its returns into the Canadian industry to ensure its long-term sustainability. adMare currently has 29 portfolio companies that have attracted $2.3 billion of risk capital, have a combined value of more than $4 billion, and have created over 1,000 jobs in Canada. For more information, please go to www.admarebio.com. | With a strong track record of globally-competitive scientific discovery, Canadian life sciences are primed to lead the world. To make this a reality, adMare BioInnovations uses its scientific and commercial expertise, specialized R&D infrastructure, and seed capital to build strong life sciences companies, develop robust ecosystems, and foster industry-ready talent. It re-invests its returns into the Canadian industry to ensure its long-term sustainability. adMare has helped build 37 companies, of which 26 are still active. These companies have attracted $2.4 billion of risk capital, have a combined value of $5.7 billion, and have created around 1,000 jobs in Canada. Our dynamic Montreal and Vancouver Innovation Centres have been home to 50 life science companies to date, with the 29 current resident companies employing over 370 life sciences professionals. The adMare Academy has trained more than 800 alumni—91% of whom are employed in the life sciences industry.
AAPharmaSyn, LLC
AAPharmaSyn, LLC (Ann Abor based and US owned) is a global research organization that provides Superior Drug Discovery Chemistry Solutions. We specialize in: 1. Medicinal Chemistry (hit to lead, lead optimization and scale up, SAR, etc. mg to 1 kg); 2. Process Research and Development (route scouting, route optimization, scale up, etc. up to 5 kg); 3. Custom and Exotic Research Tool (unique ADCs, lipids, flavonoids, carbohydrates, intermediates, etc.). AAPharmaSyn is built on the premise that application of the fundamental principles of synthetic organic chemistry toward salient problems leads to superior results. Our investment in how we solve problems and execute synthetic strategy saves money and time. | AAPharmaSyn, LLC is a US-based and owned global contract research organization (CRO) specializing in medicinal chemistry, drug discovery, process development, and non-GMP manufacturing. Headquartered in Ann Arbor, Michigan, the company was founded in 2006 by former Pfizer scientists and is staffed by senior chemists with deep expertise in organic synthesis, medicinal chemistry, and chemical process optimization. Since its inception, AAPharmaSyn has demonstrated consistent growth by delivering high-quality, reliable, and innovative solutions to a diverse client base—including government agencies, pharmaceutical and biotechnology companies of all sizes, and academic research institutions. The company’s core strengths include rigorous execution, scientific creativity, proactive problem-solving, and transparent communication. To further expand its capabilities and market reach, AAPharmaSyn actively pursues strategic collaborations with industrial partners and academic institutions, supporting the development of new products, acquisition of enabling platform technologies, and entry into emerging markets. Company Brief: 1. History: Founded in 2006 (ex-Pfizer). Based in Ann Arbor, MI (all work performed locally). BBB A+ rating. >800 projects successfully completed. 2. Team: Each team member has 10+ years of synthetic organic chemistry experience. All Ph.D.’s with multiple publications and patents. Academic pedigree: Yale, Princeton, Harvard, UC Berkeley, Purdue, UM. 3. Key Attributes: communication and problem-solving 4. Reputation: Our client testimonials speak to the value we deliver. (https://aapharmasyn.com/customer-testimonials/) Key services: • Medicinal Chemistry: high-throughput screening outcome triage, lead development, scaffold-hopping, structure-based design, structure activity relationship (SAR) development • Custom Organic and Peptide Synthesis: including ADC’s, complex carbohydrates, lipids, API impurities, intermediates, metabolites, etc. • Route Scouting and de novo Process Development: non-GMP scale-up (up to 5 kg batch size)
9Bio Therapeutics
9Bio Therapeutics is a biotech company committed to developing innovative oncology therapeutics. Our AI-guided structural biology platform integrates anatomical and biochemical contexts to design drugs that selectively target tumors. Using this approach, we generate medicines with specificity for tumors that spare healthy tissues, improving safety, efficacy, and opening the door to previously underexploited therapeutic modalities. Our pipeline includes two discovery-stage therapies: an antibody-drug conjugate (ADC) targeting chemoresistant tumor cells and an ADC targeting tumor-subverted immune cells.
53Biologics
53Biologics is a Spanish CDMO specialized in decoding biologics production, from DNA to proteins. The company provide services from preclinical development to GMP manufacturing, supporting their clients in getting their biological products to market as quickly as possible.